Thu, May 15, 8:51 PM (34 days ago)
**AIM ImmunoTech Inc. (AIM) - Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** Clinical treatment programs revenue decreased to $16,000 from $40,000, due to fluctuating patient participation. - **Net Loss:** Reduced to $3,705,000 from $5,817,000, a 36% decrease, primarily due to lower R&D and G&A expenses. - **Cash Flow:** Net cash used in operating activities decreased to $2,361,000 from $4,815,000, mainly due to reduced net loss and increased accounts payable. - **Liquidity:** As of March 31, 2025, AIM had $2,247,000 in cash, cash equivalents, and marketable investments, a decrease from December 2024. **Profit Margins and Earnings:** - **Operating Loss:** Decreased to $3,619,000 from $5,734,000. - **Gain on Investments:** Increased to $27,000 from a loss of $92,000. - **Interest Expense:** Increased to $124,000 from $72,000 due to the Note Purchase Agreement with Streeterville. **Quarterly Performance Discussion:** - **R&D Costs:** Decreased by $871,000, primarily due to lower clinical expenses and salaries. - **G&A Expenses:** Decreased by $1,270,000, mainly due to reduced legal fees and salaries. - **Investing Activities:** Cash provided by investing activities increased to $898,000 from a use of $158,000, due to increased sale and purchase of marketable investments. **Trends and Uncertainties:** - **Going Concern:** AIM faces substantial doubt regarding its ability to continue as a going concern due to operating losses and working capital deficit. - **Delisting Risk:** AIM's stock was suspended from trading on the NYSE American due to non-compliance with listing requirements and is now trading on the Pink Open Market. - **Funding:** AIM is exploring various funding options, including an ATM offering with Maxim and an equity line of credit with Atlas. **Future Operations Impact:** - **Clinical Trials:** AIM is prioritizing clinical work for pancreatic cancer, ME/CFS, and Post-COVID conditions. - **Manufacturing:** AIM is preparing to produce additional Ampligen when needed and has engaged Sterling Pharma Solutions for polymer production. - **Partnerships:** AIM is seeking co-development partners to commercialize Ampligen and Alferon N Injection. **Ticker:** AIM **Note:** All amounts are in thousands, 000s.